Lorenzo Falchi: New Insights on Treatment for Primary Cutaneous DLBCL, Leg Type
Lorenzo Falchi, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on LinkedIn about a recent paper by Giulio Cassanello et al. published on Blood Cancer Journal:
“In this open-access article we suggest that patients with primary cutaneous DLBCL, leg type may benefit from combined chemotherapy and radiation therapy.
Their CNS relapse risk is also higher and we suggest considering CNS prophylaxis when feasible.
Thank you Giulio Cassanello, Matthew Matasar, and my colleagues at MSKCC for a wonderful collaboration!”
Title: Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Authors: Giulio Cassanello, Esther Drill, Annie Qiu, Mark D. Ewalt, Paul Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Maria Lia Palomba, Andrew D. Zelenetz, Ahmet Dogan, Klaus J. Busam, Joachim Yahalom, Gilles Salles, Matthew J. Matasar & Lorenzo Falchi
More posts featuring Lorenzo Falchi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023